Drug Combination Details
| General Information of the Combination (ID: C47697) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CORO1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SKP2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PaTu 8988s | CVCL_1846 | Pancreatic adenocarcinoma | Homo sapiens | ||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells. Am J Transl Res. 2019 Feb 15;11(2):991-997. | |||
